Subscribe
Israel-Hamas Conflict
Floods
US Immigration
Soccer
Donald Trump
Volleyball
NFL
Kamala Harris
US Economy
US Politics
SEC
US Crime
Power Outages
Published

Cassava Sciences Resolves SEC Investigation - Cassava Sciences (NASDAQ:SAVA)

Summary by Benzinga
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission ("SEC") of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 P…

0 Articles

All
Left
Center
Right
BenzingaBenzinga

Cassava Sciences Resolves SEC Investigation - Cassava Sciences (NASDAQ:SAVA)

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission ("SEC") of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 P…

·New York, United States
Read Full Article
WTVBWTVB

US charges Cassava Sciences, two former executives for misleading claims about Alzheimer’s clinical trial

WASHINGTON (Reuters) – The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company’s former executives for misleading claims about the results of Alzheimer’s clinical trials. The SEC said the company’s founder and former CEO, Remi Barbier, and its former senior vice president of neuroscience, Dr. Lindsay Burns, will pay more than $40 million to settle charges. (Reporting by Jasper War…

Read Full Article
MarketWatchMarketWatch

Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims

Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.

·United States
Read Full Article
STATSTAT

Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines

Cassava was charged Thursday by the SEC with making misleading claims in 2020 about trials for its Alzheimer's drug, and agreed to pay fines.

·Boston, United States
Read Full Article
InvezzInvezz

SEC Charges Cassava Sciences, Two Former Executives for Misleading Claims About Alzheimer’s Clinical Trial

September 26, 2024 6:14 PM EDT | Source: Newsfile SEC Press Digest Washington, D.C.–(Newsfile Corp. – September 26, 2024) – The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and its former Senior Vice President of Neuroscience, Dr. Lindsay Burns, will pay more than $40 million to settle charges related to misleading statements made in September 2020 about the results of a Ph…

Read Full Article
stocktitan.netstocktitan.net

Cassava Sciences Resolves SEC Investigation

Cassava Sciences settles SEC probe with $40M penalty, focuses on Alzheimer's drug trials. New leadership appointed as company maintains year-end cash estimates despite setback. Learn about the impact on SAVA stock and future outlook.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

AlzheimerAlzheimer
SECSEC
Austin, TexasAustin, Texas
Trending Topics
Ground News logo
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal